Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25C | P30307 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316388 | 0.85 | CYP1A2 (0.40) | CYP1A1CYP1A2CYP1B1SLC6A3HSD11B1 | |
| SCHEMBL24316476 | 0.85 | SLC6A3 (0.41) | CYP1A1CYP1A2CYP1B1SLC6A3HSD11B1 | |
| SCHEMBL25818513 | 0.82 | AHR (0.47) | AHRCDC25ACDC25C | |
| SCHEMBL25818854 | 0.80 | ALOX5 (0.36) | AHRCYP1A1CYP1A2CYP1B1CDC25A | |
| SCHEMBL25818688 | 0.78 | AHR (0.41) | AHRCYP1A1CYP1A2CYP1B1SLC6A3 | |
| SCHEMBL24316387 | 0.74 | CYP1A2 (0.38) | CYP1A1CYP1A2CYP1B1SLC6A3HSD11B1 | |
| SCHEMBL25818547 | 0.74 | AHR (0.41) | AHR | |
| SCHEMBL25038246 | 0.73 | CYP1A2 (0.35) | CYP1A1CYP1A2CYP1B1SLC6A3LTB4R | |
| SCHEMBL25037645 | 0.73 | SLC6A3 (0.36) | CYP1A1CYP1A2CYP1B1SLC6A3 | |
| SCHEMBL25818499 | 0.73 | AHR (0.54) | AHRCYP1A1CYP1A2CYP1B1CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230217825-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230217825-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230217825-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | OR10J3, AOC2, EPCAM | AHR 3212/4885CYP1A1 1060/4885CYP1A2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.